Cargando…
Surveillance of gynecologic cancer patients post-COVID-19 vaccine: Are CA-125 levels reliable?
OBJECTIVE: The COVID-19 vaccine is known to instigate an inflammatory response that impacts cancer testing. We aimed to evaluate carbohydrate antigen 125 (CA-125) trends in gynecologic oncology patients in surveillance following COVID-19 vaccination to inform clinical practice. METHODS: This was a s...
Autores principales: | Thayer, Elizabeth, Walsh, Lindsay, Leung, Katherine, Korets, Sharmilee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859765/ https://www.ncbi.nlm.nih.gov/pubmed/36714374 http://dx.doi.org/10.1016/j.gore.2023.101140 |
Ejemplares similares
-
An Antibody‐Tumor Model for the Targeting of CA125‐producing Gynecologic Malignancies
por: Saga, Tsuneo, et al.
Publicado: (1990) -
Clinical Applicability of Tissue Polypeptide Antigen and CA-125 in Gynecological Malignancies
por: Schröder, Lars, et al.
Publicado: (2023) -
CA-125 monitoring in gynecologic cancer patients with COVID-19: A case series
por: Folsom, Susan M., et al.
Publicado: (2022) -
Rising CA-125 (Cancer Antigen 125) Levels: Cancer Recurrence or a Vaccine Reaction?
por: Parkash, Jasmita, et al.
Publicado: (2023) -
CA-125 monitoring in gynecologic cancer patients with COVID-19: A case series (413)
por: Mumford, Brigid, et al.
Publicado: (2022)